Bayer AG (BAYRY)
OTHER OTC:BAYRY
Want to see BAYRY full AI Analyst Report?
BAYRY Stock Chart & Stats
$11.02
-$0.08(-1.46%)
At close: 4:00 PM EST
$11.02
-$0.08(-1.46%)
Day’s Range― - ―
52-Week Range$6.72 - $14.56
Previous CloseN/A
Volume306.92K
Average Volume (3M)889.54K
Market Cap
$44.81B
Enterprise Value$71.70B
Total Cash (Recent Filing)$5.73B
Total Debt (Recent Filing)$38.93B
Price to Earnings (P/E)3.5
Beta0.48
Next Earnings
Aug 04, 2026EPS Estimate
0.23Next Dividend Ex-DateN/A
Dividend Yield0.29%
Share Statistics
EPS (TTM)-0.57
Shares Outstanding3,929,696,000
10 Day Avg. Volume307,649
30 Day Avg. Volume889,540
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)1.40
Price to Sales (P/S)0.83
P/FCF Ratio18.08
Enterprise Value/Market Cap1.60
Enterprise Value/Revenue1.58
Enterprise Value/Gross Profit2.66
Enterprise Value/Ebitda9.83
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.28
Revenue Forecast (FY)$53.30B
Bulls Say, Bears Say
Bulls Say
Consistent Cash GenerationBayer has delivered positive operating and free cash flow across reported periods, which is durable cash-generation capacity separate from reported net losses. Persistent FCF provides a structural buffer to fund R&D, launches, dividend policy and large one-off items, improving resilience over the next 2–6 months even as FCF weakens.
High And Stable Gross MarginsA sustained gross margin near 59% indicates strong product economics and pricing power across segments. High gross margins create operating leverage that supports investment in pipelines and digitalization, helping the company sustain profitability improvements as volumes or mix recover over a medium-term horizon.
Pharma Launch Momentum & Faster Time-to-MarketDemonstrated rapid successful launches and a strengthened pipeline (multiple approvals and advances) indicate durable revenue drivers in Pharmaceuticals. Combined with organizational simplification and DSO productivity, faster commercialization supports sustainable top-line recovery and margin expansion over the coming months as new brands scale.
Bears Say
Large Litigation LiabilitiesMaterial litigation liabilities and an anticipated ~€5bn payout are structural cash drains that will push 2026 free cash flow negative and force financing. This reduces capacity for discretionary investment and raises refinancing and rating risks, creating a multi-month to multi-year headwind to balance-sheet repair.
Multi-year Revenue DeclineA sustained top-line decline (~25% TTM) signals structural demand and mix challenges across segments. Persistent revenue weakness constrains scale benefits, makes margin recovery reliant on cost cuts and new-product ramp-ups, and increases sensitivity to competitive and regulatory shocks over the medium term.
Elevated Leverage And Weak ReturnsDebt running near 1.35x equity while profitability is negative limits financial flexibility. Elevated leverage increases interest and refinancing sensitivity, constrains strategic options (M&A, buybacks), and heightens reliance on external financing to cover litigation payouts and working capital needs in the medium term.
Bayer News
BAYRY FAQ
What was Bayer AG’s price range in the past 12 months?
Bayer AG lowest stock price was $6.72 and its highest was $14.56 in the past 12 months.
What is Bayer AG’s market cap?
Bayer AG’s market cap is $44.81B.
When is Bayer AG’s upcoming earnings report date?
Bayer AG’s upcoming earnings report date is Aug 04, 2026 which is in 75 days.
How were Bayer AG’s earnings last quarter?
Bayer AG released its earnings results on May 12, 2026. The company reported $0.795 earnings per share for the quarter, beating the consensus estimate of $0.676 by $0.119.
Is Bayer AG overvalued?
According to Wall Street analysts Bayer AG’s price is currently Overvalued.
Does Bayer AG pay dividends?
Bayer AG pays a Annually dividend of $0.031 which represents an annual dividend yield of 0.29%. See more information on Bayer AG dividends here
What is Bayer AG’s EPS estimate?
Bayer AG’s EPS estimate is 0.23.
How many shares outstanding does Bayer AG have?
Bayer AG has 3,929,696,000 shares outstanding.
What happened to Bayer AG’s price movement after its last earnings report?
Bayer AG reported an EPS of $0.795 in its last earnings report, beating expectations of $0.676. Following the earnings report the stock price went up 3.278%.
Which hedge fund is a major shareholder of Bayer AG?
Currently, no hedge funds are holding shares in BAYRY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bayer Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
BAYRY Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 33.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
News Sentiment
Bullish
Bullish news 79%
Bearish news 14%
Bearish news 14%
Technicals
SMA
Positive
20 days / 200 days
Momentum
73.00%
12-Months-Change
Fundamentals
Return on Equity
-7.52%
Trailing 12-Months
Asset Growth
5.46%
Trailing 12-Months
Company Description
Bayer AG
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.
BAYRY Company Deck
BAYRY Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced clear operational progress—delivery of raised guidance, improved launch momentum in Pharma, meaningful DSO-driven cost savings, and a reduced net financial debt position in 2025—against substantial legal and cashflow headwinds. Management articulated tangible growth drivers across Crop Science, Pharma and Consumer Health and concrete cost-savings milestones, but also disclosed large litigation provisions (EUR 11.8 billion liabilities), expected negative free cash flow in 2026 due to ~EUR 5 billion litigation-related payouts, projected net debt increase and significant product declines (notably Xarelto and Eylea). Given the mix of strong operational execution and material financial/legal risks that will weigh on near-term cash flow and balance-sheet metrics, the tone of the call is cautiously constructive but realistic about the challenges ahead.View all BAYRY earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
0.17% Mutual Funds
0.17% Other Institutional Investors
99.55% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---